Improving outcomes in scleroderma: recent progress of cell-based therapies

Area of Science:

• Immunology
• Rheumatology
• Cell Therapy

Background:

• Scleroderma is a rare, systemic autoimmune disease characterized by fibrosis and immune dysregulation.
• Diffuse cutaneous scleroderma (dcSSc), a severe form, lacks curative treatments and has limited options.
• Current treatments like hematopoietic stem cell transplantation face challenges including toxicity and disease recurrence.

Approach:

• This review examines novel cell therapies for scleroderma and other autoimmune diseases.
• Focuses on mesenchymal stem cells, CAR-based therapy, tolerogenic dendritic cells, and facilitating cells.
• Evaluates their potential to restore self-tolerance with better safety profiles.

Key Points:

• Novel cell therapies offer potential disease modification for dcSSc.
• These therapies aim to restore self-tolerance, a key feature of autoimmune diseases.
• Mesenchymal stem cells, CAR-T cells, and dendritic cell therapies are among those explored.

Conclusions:

• Evolving cell therapies present a promising avenue for treating dcSSc.
• These approaches may offer improved safety and tolerability compared to existing treatments.
• Further research into cell therapies could revolutionize autoimmune disease management.